Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04179 (
MnSOD
)
2,777
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oxidative damage has been suggested to play a role in the pathogenesis of
basal cell carcinoma
(
BCC
). This study illustrated an involvement of oxidative DNA damage and changes in antioxidant defenses in
BCC
by conducting a case-control study (24 controls and 24
BCC
patients) and assessing urinary 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxo-dGuo), plasma antioxidant defenses including catalase (CAT), glutathione peroxidase (GPx), NQO1, and total superoxide dismutase (SOD) activities, and glutathione (GSH) levels before surgery and 1 month after surgery. 8-oxo-dGuo expressions as well as protein and mRNA expressions of DNA repair enzyme hOGG1 and antioxidant defenses (CAT, GCLC, GPx, Nrf2, and
MnSOD
) in nonneoplastic epidermis of control and
BCC
tissues were also determined. This study observed induction in urinary 8-oxo-dGuo, increased 8-oxo-dGuo expression, and reduced hOGG1 protein and mRNA in
BCC
tissues, decreased activities of CAT, GPx, and NQO1, but elevated SOD activities and GSH levels in
BCC
patients and reduction of all antioxidant proteins and genes studied in
BCC
tissues. Furthermore, decreased plasma antioxidant activities in
BCC
patients were restored at 1 month after operation compared with preoperative levels. Herein, we concluded that
BCC
patients were associated with oxidative DNA damage and depletion of antioxidant defenses and surgical removal of
BCC
correlated with improved redox status.
...
PMID:A Case-Control Study of Involvement of Oxidative DNA Damage and Alteration of Antioxidant Defense System in Patients with Basal Cell Carcinoma: Modulation by Tumor Removal. 2705 81